EcoDrugPlus

Galectin 1

Ensembl ID : ENSSARG00000013937
Gene Symbol: LGALS1
1 External references
379 Possible Orthologues:

Galectin 3

Ensembl ID : ENSSARG00000000068
Gene Symbol: LGALS3
1 External references
218 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha1

Ensembl ID : ENSSARG00000013866
Gene Symbol: GABRA1
1 External references
202 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha2

Ensembl ID : ENSSARG00000007171
Gene Symbol: GABRA2
1 External references
253 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha4

Ensembl ID : ENSSARG00000002682
Gene Symbol: GABRA4
1 External references
201 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha5

Ensembl ID : ENSSARG00000013058
Gene Symbol: GABRA5
3 External references
264 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta1

Ensembl ID : ENSSARG00000002573
Gene Symbol: GABRB1
1 External references
102 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta2

Ensembl ID : ENSSARG00000002218
Gene Symbol: GABRB2
1 External references
275 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma1

Ensembl ID : ENSSARG00000008636
Gene Symbol: GABRG1
1 External references
188 Possible Orthologues:

Gastric Inhibitory Polypeptide Receptor

Ensembl ID : ENSSARG00000009137
Gene Symbol: GIPR
1 External references
93 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSSARG00000003685
Gene Symbol: GLP2R
1 External references
205 Possible Orthologues:

Glucokinase

Ensembl ID : ENSSARG00000006856
Gene Symbol: GCK
1 External references
211 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).